LA SB43

Establishes the Psychedelic-Assisted Therapy Program within the Louisiana Department of Health, Office of Behavioral Health, effective August 1, 2026

Authorizes clinical studies using ibogaine and psilocybin for treatment of opioid use disorders, co-occurring substance use disorders, and treatment-resistant neurological or mental health conditions at approved academic health centers

Allows parishes to use opioid settlement funds to enroll eligible patients in the clinical studies, with additional funding permitted from federal sources, gifts, grants, and donations

Requires participating academic health centers to comply with FDA investigational new drug applications, DEA Schedule I research registration, and Institutional Review Board approval

Mandates annual progress reports from academic health centers to the department, with a compiled legislative report due by February 1st each year